ANBIO BIOTECHNOLOGY LTD (NNNN) Fundamental Analysis & Valuation

NASDAQ:NNNN • KYG0367B1059

21.8 USD
-2.42 (-9.99%)
At close: Mar 5, 2026
22.23 USD
+0.43 (+1.97%)
After Hours: 3/5/2026, 8:11:18 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This NNNN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Overall NNNN gets a fundamental rating of 6 out of 10. We evaluated NNNN against 520 industry peers in the Biotechnology industry. NNNN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. NNNN is quite expensive at the moment. It does show a decent growth rate. With these ratings, NNNN could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

7

1. NNNN Profitability Analysis

1.1 Basic Checks

  • NNNN had positive earnings in the past year.
  • NNNN had a positive operating cash flow in the past year.
NNNN Yearly Net Income VS EBIT VS OCF VS FCFNNNN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2M 4M 6M 8M 10M

1.2 Ratios

  • NNNN's Return On Assets of 31.55% is amongst the best of the industry. NNNN outperforms 98.27% of its industry peers.
  • NNNN has a Return On Equity of 34.72%. This is amongst the best in the industry. NNNN outperforms 97.50% of its industry peers.
  • NNNN has a better Return On Invested Capital (25.70%) than 98.46% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for NNNN is significantly above the industry average of 19.05%.
Industry RankSector Rank
ROA 31.55%
ROE 34.72%
ROIC 25.71%
ROA(3y)32.84%
ROA(5y)N/A
ROE(3y)36.27%
ROE(5y)N/A
ROIC(3y)27.94%
ROIC(5y)N/A
NNNN Yearly ROA, ROE, ROICNNNN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 20 40 60 80

1.3 Margins

  • NNNN's Profit Margin of 42.53% is amongst the best of the industry. NNNN outperforms 98.08% of its industry peers.
  • In the last couple of years the Profit Margin of NNNN has declined.
  • The Operating Margin of NNNN (39.86%) is better than 98.27% of its industry peers.
  • NNNN's Operating Margin has declined in the last couple of years.
  • The Gross Margin of NNNN (69.80%) is better than 80.96% of its industry peers.
  • NNNN's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 39.86%
PM (TTM) 42.53%
GM 69.8%
OM growth 3Y-23.96%
OM growth 5YN/A
PM growth 3Y-20.3%
PM growth 5YN/A
GM growth 3Y7.8%
GM growth 5YN/A
NNNN Yearly Profit, Operating, Gross MarginsNNNN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

10

2. NNNN Health Analysis

2.1 Basic Checks

  • NNNN has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for NNNN has been reduced compared to 1 year ago.
  • NNNN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NNNN Yearly Shares OutstandingNNNN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 50M 100M
NNNN Yearly Total Debt VS Total AssetsNNNN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • NNNN has an Altman-Z score of 372.69. This indicates that NNNN is financially healthy and has little risk of bankruptcy at the moment.
  • NNNN's Altman-Z score of 372.69 is amongst the best of the industry. NNNN outperforms 99.81% of its industry peers.
  • NNNN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 372.69
ROIC/WACC3.45
WACC7.45%
NNNN Yearly LT Debt VS Equity VS FCFNNNN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 5M 10M 15M

2.3 Liquidity

  • NNNN has a Current Ratio of 10.71. This indicates that NNNN is financially healthy and has no problem in meeting its short term obligations.
  • NNNN has a Current ratio of 10.71. This is amongst the best in the industry. NNNN outperforms 84.23% of its industry peers.
  • NNNN has a Quick Ratio of 10.71. This indicates that NNNN is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 10.71, NNNN belongs to the best of the industry, outperforming 84.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.71
Quick Ratio 10.71
NNNN Yearly Current Assets VS Current LiabilitesNNNN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. NNNN Growth Analysis

3.1 Past

  • NNNN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.03%, which is quite impressive.
  • Measured over the past years, NNNN shows a very strong growth in Earnings Per Share. The EPS has been growing by 46.62% on average per year.
  • Looking at the last year, NNNN shows a small growth in Revenue. The Revenue has grown by 1.66% in the last year.
  • Measured over the past years, NNNN shows a very strong growth in Revenue. The Revenue has been growing by 22.72% on average per year.
EPS 1Y (TTM)47.03%
EPS 3Y46.62%
EPS 5YN/A
EPS Q2Q%6.72%
Revenue 1Y (TTM)1.66%
Revenue growth 3Y22.72%
Revenue growth 5YN/A
Sales Q2Q%-21.63%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NNNN Yearly Revenue VS EstimatesNNNN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

Find the best growth stocksShow best growing peers

3

4. NNNN Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 155.71, the valuation of NNNN can be described as expensive.
  • Based on the Price/Earnings ratio, NNNN is valued cheaply inside the industry as 87.69% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of NNNN to the average of the S&P500 Index (26.74), we can say NNNN is valued expensively.
Industry RankSector Rank
PE 155.71
Fwd PE N/A
NNNN Price Earnings VS Forward Price EarningsNNNN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • NNNN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NNNN is cheaper than 90.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 459.91
EV/EBITDA N/A
NNNN Per share dataNNNN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3

4.3 Compensation for Growth

  • NNNN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NNNN Dividend Analysis

5.1 Amount

  • NNNN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NNNN Fundamentals: All Metrics, Ratios and Statistics

ANBIO BIOTECHNOLOGY LTD

NASDAQ:NNNN (3/5/2026, 8:11:18 PM)

After market: 22.23 +0.43 (+1.97%)

21.8

-2.42 (-9.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)04-27
Inst Owners4.94%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap956.80M
Revenue(TTM)12.77M
Net Income(TTM)5.97M
AnalystsN/A
Price TargetN/A
Short Float %0.12%
Short Ratio0.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 155.71
Fwd PE N/A
P/S 68.17
P/FCF 459.91
P/OCF 459.91
P/B 55.66
P/tB 55.66
EV/EBITDA N/A
EPS(TTM)0.14
EY0.64%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.05
FCFY0.22%
OCF(TTM)0.05
OCFY0.22%
SpS0.32
BVpS0.39
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.11
Profitability
Industry RankSector Rank
ROA 31.55%
ROE 34.72%
ROCE 32.54%
ROIC 25.71%
ROICexc 81.37%
ROICexgc 81.37%
OM 39.86%
PM (TTM) 42.53%
GM 69.8%
FCFM 14.82%
ROA(3y)32.84%
ROA(5y)N/A
ROE(3y)36.27%
ROE(5y)N/A
ROIC(3y)27.94%
ROIC(5y)N/A
ROICexc(3y)88.97%
ROICexc(5y)N/A
ROICexgc(3y)88.97%
ROICexgc(5y)N/A
ROCE(3y)35.37%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-23.96%
OM growth 5YN/A
PM growth 3Y-20.3%
PM growth 5YN/A
GM growth 3Y7.8%
GM growth 5YN/A
F-Score6
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality 34.85%
Current Ratio 10.71
Quick Ratio 10.71
Altman-Z 372.69
F-Score6
WACC7.45%
ROIC/WACC3.45
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)57.33%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.03%
EPS 3Y46.62%
EPS 5YN/A
EPS Q2Q%6.72%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.66%
Revenue growth 3Y22.72%
Revenue growth 5YN/A
Sales Q2Q%-21.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y65.39%
EBIT growth 3Y-6.69%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y131.57%
FCF growth 3Y-20.76%
FCF growth 5YN/A
OCF growth 1Y131.57%
OCF growth 3Y-20.76%
OCF growth 5YN/A

ANBIO BIOTECHNOLOGY LTD / NNNN FAQ

Can you provide the ChartMill fundamental rating for ANBIO BIOTECHNOLOGY LTD?

ChartMill assigns a fundamental rating of 6 / 10 to NNNN.


What is the valuation status for NNNN stock?

ChartMill assigns a valuation rating of 3 / 10 to ANBIO BIOTECHNOLOGY LTD (NNNN). This can be considered as Overvalued.


Can you provide the profitability details for ANBIO BIOTECHNOLOGY LTD?

ANBIO BIOTECHNOLOGY LTD (NNNN) has a profitability rating of 7 / 10.


How financially healthy is ANBIO BIOTECHNOLOGY LTD?

The financial health rating of ANBIO BIOTECHNOLOGY LTD (NNNN) is 10 / 10.